Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
- Description:
Fluorescent H3 histamine receptor antagonist
- Description:
Fluorescent M3 muscarinic receptor antagonist
- Description:
Fluorescent GABAB receptor antagonist
- Description:
Fluorescent 5-HT1A receptor antagonist
- Description:
Fluorescent 5-HT2A receptor antagonist
Caffeine (HB2846)
Description:Non-selective, competitive adenosine receptor antagonist / PDE inhibitor
(S)-4-Carboxyphenylglycine (HB0049)
Description:Competitive, selective group 1 mGlu antagonist
Purity:>99%